Tonix Pharmaceuticals Holding Corp. (TNXP) – Investment Analysts’ Recent Ratings Updates

tonix-pharmaceuticals-holding-corp-tnxp-8211-investment-analysts8217-recent-ratings-updates.png

Several analysts have recently updated their ratings and price targets for Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP):

9/7/2016 – Tonix Pharmaceuticals Holding Corp. was downgraded by analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating.
9/7/2016 – Tonix Pharmaceuticals Holding Corp. was downgraded by analysts at Roth Capital from a “buy” rating to a “neutral” rating.
9/7/2016 – Tonix Pharmaceuticals Holding Corp. was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
8/24/2016 – Tonix Pharmaceuticals Holding Corp. had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $5.00 price target on the stock.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded up 1.993% on Wednesday, reaching $0.788. The company’s stock had a trading volume of 1,306,974 shares. The firm’s 50 day moving average price is $2.06 and its 200-day moving average price is $2.30. The company’s market capitalization is $20.38 million. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $0.75 and a 52 week high of $7.95.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/14/tonix-pharmaceuticals-holding-corp-tnxp-investment-analysts-recent-ratings-updates.html

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.05. On average, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post ($1.70) EPS for the current year.
In related news, insider Bruce Daugherty purchased 100,000 shares of the company’s stock in a transaction dated Tuesday, June 21st. The shares were acquired at an average cost of $2.00 per share, for a total transaction of $200,000.00. Following the transaction, the insider now owns 65,777 shares of the company’s stock, valued at $131,554. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director John B. Rhodes purchased 25,000 shares of the company’s stock in a transaction dated Tuesday, June 21st. The shares were bought at an average price of $2.00 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the director now directly owns 112,196 shares in the company, valued at approximately $224,392. The disclosure for this purchase can be found here. Insiders own 10.20% of the company’s stock.

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tonix Pharmaceuticals Holding Corp and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Tonix Pharmaceuticals Holding Corp. (TNXP) – Investment Analysts’ Recent Ratings Updates"

Leave a comment

Your email address will not be published.

*